Welcome to our dedicated page for Purple Biotech news (Ticker: PPBT), a resource for investors and traders seeking the latest updates and insights on Purple Biotech stock.
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company based in Rehovot, Israel, dedicated to developing innovative cancer therapies that harness the tumor microenvironment to overcome immune evasion and drug resistance. The company's oncology pipeline includes two main drug candidates, CM24 and NT219, along with a pioneering platform of conditionally-activated tri-specific antibodies.
CM24 is a multi-functional immune checkpoint inhibitor undergoing Phase 2 clinical trials for the treatment of pancreatic ductal adenocarcinoma (PDAC). This study, in collaboration with Bristol Myers Squibb, is evaluating CM24 combined with nivolumab and chemotherapy as a second-line treatment. The primary endpoint is overall survival, with interim results expected by mid-2024 and topline data by the end of the same year.
NT219 is a small molecule dual inhibitor targeting IRS1/2 and STAT3. It has shown promising results in a Phase 1/2 dose escalation study for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). A Phase 2 study is planned for NT219 in combination with cetuximab, set to begin in the first half of 2024.
Additionally, Purple Biotech’s tri-specific antibody platform aims to conditionally activate T cells and natural killer (NK) cells within the tumor microenvironment. The platform's lead candidate, IM1240, targets 5T4, a tumor-associated antigen, and is designed to induce a localized immune response while minimizing off-tumor side effects.
Recent financial reports indicate that Purple Biotech has a solid cash runway into the first half of 2025, thanks to strategic funding and partnerships. The company’s research and development expenses have seen a slight increase due to ongoing clinical trials, while selling, general, and administrative expenses have decreased.
For more detailed information and the latest updates, visit Purple Biotech’s website.
FAQ
What is the current stock price of Purple Biotech (PPBT)?
What is the market cap of Purple Biotech (PPBT)?
What is Purple Biotech Ltd. focused on?
What are the main drug candidates in Purple Biotech's pipeline?
What is CM24?
What is NT219?
What is unique about Purple Biotech’s tri-specific antibody platform?
What recent milestones has Purple Biotech achieved?
What are Purple Biotech's financial highlights?
Who are Purple Biotech's key partners?
Where is Purple Biotech headquartered?
Where can I find more information about Purple Biotech?
